Understand the source comparison
Calculate Follistatin-344 Dosage: Protocol Comparison
Different research objectives require different Follistatin-344 dosing protocols. The table below compares three common approaches. Acute high-dose injury response, chronic moderate-dose muscle hypertrophy, and low-dose extended longevity studies. Showing how
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different research objectives require different Follistatin-344 dosing protocols. The table below compares three common approaches. Acute high-dose injury response, chronic moderate-dose muscle hypertrophy, and low-dose extended longevity studies. Showing how to calculate Follistatin-344 dosage parameters for each.
- | Protocol Type | Dose Range (mcg/kg) | Frequency | Reconstitution Example (1mg vial) | Injection Volume (Mouse, 28g) | Study Duration | Professional Assessment ||—|—|—|—|—|—|| Acute Injury Response | 300–500 mcg/kg | Single dose or 3 doses over 7 days | 1mg in 1mL = 1000mcg/mL (adjusted 980mcg/mL at 98% purity) | 8.4–14mcg ÷ 980mcg/mL = 0.0086–0.014mL (8.6–14 units) | 1–4 weeks post-injury | Used in muscle injury, ischemia, or regeneration studies where maximum immediate response is prioritized. High dose increases risk of off-target effects but maximizes myostatin inhibition during critical recovery window. || Chronic Hypertrophy | 100–200 mcg/kg | 2–3× per week | 1mg in 2mL = 500mcg/mL (adjusted 490mcg/mL at 98% purity) | 2.8–5.6mcg ÷ 490mcg/mL = 0.0057–0.011mL (5.7–11 units) | 8–12 weeks | Standard protocol for muscle mass and strength studies. Twice-weekly dosing accounts for Follistatin-344 half-life (approximately 30–40 hours in circulation). Most published hypertrophy data use
- The 'Professional Assessment' column is essential. It explains why dose and frequency differ based on study objectives. Acute injury protocols use single high doses to saturate myostatin receptors during the immediate post-injury inflammation phase when endogenous myostatin expression peaks. Chronic hypertrophy studies space doses 3–4 days apart to maintain steady-state myostatin inhibition without excessive accumulation, as Follistatin-344 circulating half-life is 30–40 hours but tissue retention extends biological activity. Low-dose longevity studies prioritize minimal intervention and examine whether partial myostatin inhibition. Rather than maximal suppression. Produces metabolic benefits with fewer off-target effects.
- When comparing published studies, always verify that dose is reported in mcg/kg body weight, not absolute mcg. A study reporting '100mcg per injection' without body weight context cannot be directly compared to one reporting 100mcg/kg. The former might represent 25mcg/kg in a large rat or 400mcg/kg in a small mouse. This is the single most common source of confusion when researchers attempt to replicate published Follistatin-344 protocols. Calculate Follistatin-344 dosage in mcg/kg, document animal body weight at every injection, and report both absolute dose and dose rate in your methods section for reproducibility.